



Our STN: BL 125679/0

BLA APPROVAL
July 23, 2019

Abbott GmbH & Co. KG
Attention: Ms. Deborah Hinkley
Abbott Laboratories
Dept. 09TR, Bldg. AP8A
100 Abbott Park Road
Abbott Park, IL 60064-6092

Dear Ms. Hinkley:

Please refer to your Biologics License Application (BLA) submitted May 17, 2018, received May 24, 2018, under section 351(a) of the Public Health Service Act (PHS Act) for Human Immunodeficiency Virus Types 1 and 2 (*E coli*, *B megaterium*, Recombinant) Antigen, Antibody (p24) and Synthetic Peptides.

LICENSING

We have approved your BLA for the Human Immunodeficiency Virus Types 1 and 2 (*E coli*, *B megaterium*, Recombinant) Antigen, Antibody (p24) and Synthetic Peptides effective this date. You are hereby authorized to introduce or deliver for introduction into interstate commerce, the Human Immunodeficiency Virus Types 1 and 2 (*E coli*, *B megaterium*, Recombinant) Antigen, Antibody (p24) and Synthetic Peptides under your existing Department of Health and Human Services U.S. License No. 2095. The Alinity s HIV Ag/Ab Combo assay is a chemiluminescent microparticle immunoassay (CMIA) used for the simultaneous qualitative detection of human immunodeficiency virus (HIV) p24 antigen and antibodies to HIV type 1 (HIV-1 group M and group O) and/or type 2 (HIV-2) in human serum and plasma specimens on the Alinity s System.

The Alinity s HIV Ag/Ab Combo assay is intended to screen individual human donors, including volunteer donors of whole blood and blood components, and other living donors for the presence of anti-HIV-1/HIV-2 and HIV-1 p24 antigen. The assay is also intended for use in testing serum and plasma specimens to screen organ donors when specimens are obtained while the donor's heart is still beating, and in testing serum specimens to screen cadaveric (nonheart-beating) donors. It is not intended for use on cord blood specimens.

The review of this product was associated with the following National Clinical Trial (NCT) number: 03285295.

MANUFACTURING LOCATIONS

Under this license, you are approved to manufacture the Human Immunodeficiency Virus Types 1 and 2 (*E coli*, *B megaterium*, Recombinant) Antigen, Antibody (p24) and Synthetic Peptides at your facilities located at Abbott GmbH & Co. KG at Max-Planck-Ring 2 in Wiesbaden, Germany. You may label your product with the proprietary name Human Immunodeficiency Virus Types 1 and 2 (*E coli*, *B megaterium*, Recombinant) Antigen, Antibody (p24) and Synthetic Peptides and market it as approved in your license application.

ADVISORY COMMITTEE

We did not refer your application to the Blood Products Advisory Committee because our review of information submitted in your BLA, including the clinical study design and trial results, did not raise concerns or controversial issues that would have benefited from an advisory committee discussion.

DATING PERIOD

The dating period for Human Immunodeficiency Virus Types 1 and 2 (*E coli*, *B megaterium*, Recombinant) Antigen, Antibody (p24) and Synthetic Peptides kits shall be 12-months from the date of manufacture when stored at the appropriate temperatures indicated for each component. The date of manufacture shall be defined in accordance with 21 CFR 610.50.

FDA LOT RELEASE

Please submit final container samples of the product Abbott Alinity s HIV Ag/Ab Combo and each kit component in final containers together with protocols showing results of all applicable tests. You may not distribute any lots of product until you receive a notification of release from the Director, Center for Biologics Evaluation and Research (CBER).

BIOLOGICAL PRODUCT DEVIATIONS

You must submit reports of biological product deviations under 21 CFR 600.14. You should identify and investigate all manufacturing deviations promptly, including those associated with processing, testing, packaging, labeling, storage, holding and distribution. If the deviation involves a distributed product, may affect the safety, purity, or potency of the product, and meets the other criteria in the regulation, you must submit a report on Form FDA 3486 to the Director, Office of Compliance and Biologics Quality, at the following address:

Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Ave.
WO71-G112
Silver Spring, MD 20993-0002

MANUFACTURING CHANGES

You must submit information to your BLA for our review and written approval under 21 CFR 601.12 for any changes in, including but not limited to, the manufacturing, testing, packaging or labeling of the Human Immunodeficiency Virus Types 1 and 2 (*E coli*, *B megaterium*, Recombinant) Antigen, Antibody (p24) and Synthetic Peptides, or in the manufacturing facilities.

LABELING

We hereby approve the draft package insert labeling, carton and container labeling submitted under amendment 125679\0\9, dated July 12, 2019. This is a reminder that as of September 24, 2014, medical devices that are licensed under the PHS Act are subject to certain provisions of the final Unique Device Identifier (UDI) rule. These provisions include the requirement to provide a UDI on the device label and packages (21 CFR 801.20), format dates on the device label in accordance with 21 CFR 801.18, and submit data to the Global Unique Device Identification Database (GUDID) (21 CFR 830 Subpart E). Additionally, please identify each device identifier implemented for the subject device, and the device identifiers that have been discontinued for the subject device as a labeling change in an annual report consistent with 21 CFR 601.12(f)(3). For more information on these requirements, please see the UDI website at <http://www.fda.gov/udi>.

Please submit all final printed labeling as a PDF electronic copy (eCopy) at the time of use and include implementation information on Form FDA 356h as appropriate.

Two draft copies of the proposed introductory advertising or promotional labeling may be voluntarily submitted for advisory comment with a completed Form FDA 2253 to the Advertising and Promotional Labeling Branch at the following address:

Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Ave.
WO71-G112
Silver Spring, MD 20993-0002

ADVERSE EVENT REPORTING

You must submit adverse experience reports in accordance with the Medical Device Reporting (MDR) requirements for medical devices (21 CFR 803) as required by 21 CFR 600.80(k)(2). Because your product is characterized as a device as well as a biologic, submit these reports to the MedWatch System using MedWatch Reporting Form 3500A or an electronic equivalent. Please refer to the *Questions and Answers about eMDR – Electronic Medical Device Reporting – Guidance for Industry, User Facilities and FDA Staff* at

<https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm175805.htm>.

Required reports are to be submitted to:

Food and Drug Administration
Center for Devices and Radiological Health
MDR Policy Branch
10903 New Hampshire Avenue
WO Bldg. 66, Room 3217
Silver Spring, MD 20993-0002

Sincerely,

Nicole Verdun, MD
Office Director
Office of Blood Research and Review
Center for Biologics Evaluation and Research